HCS Pharma uses ImageXpress Micro Confocal Systems for phenotypic screening of physiologically relevant 3D cell models

HCS Pharma is a biotechnology start-up focused on in vitro preclinical research and development. The company specializes in multi-parametric cell imaging assays using High-Content Analysis (HCA) and High-Content Screening (HCS) approaches. This allows them to save time and money by investigating several different parameters within the same experiment. The team, led by Nathalie and Grégory Maubon, performs both primary and secondary screens and develops new assays and 2D/3D cell culture models. These can be used for services in different application areas such as toxicology, pharmacology, dermo-cosmetics and nutraceutics.

HCS Pharma creates innovative 3D cellular models which enable researchers to perform phenotypic screening on more relevant 3D cellular assays that also consider the extracellular matrix (ECM). To reach this goal, HCS Pharma has recently acquired BIOMIMESYS^® technology, which is a unique and natural hyaluronic acid-based hydroscaffold, biofunctionalized with other ECM components to better mimic the microenvironment of every organ!

The team needed to implement 3D confocal imaging using powerful and reliable high-throughput systems that could be integrated within a robotic platform, allowing high-throughput imaging. Specifically, the team needed:

• Confocal imaging to perform 3D reconstructions
• A high signal-to-noise ratio to maximize acquisition speed
• A fully integrated platform, from incubators to imagers
• Imaging software to perform high-throughput 3D image analysis

“We needed a solution which would maximize the rentability of our studies by enabling us to offer more parameter extractions in less time”, says Nathalie Maubon.

See how the team save time and money with automated High-Content Screening (HCS) and imaging approaches, in collaboration with Molecular Devices.

View Case Study

Learn more - cell imaging systems

more news from Molecular Devices